Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).[2][3]
Panitumumab is manufactured by Amgen and was originally developed by Abgenix Inc.
In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab.[4]
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ ab"Vectibix- panitumumab solution". DailyMed. 25 August 2021. Archived from the original on 6 April 2022. Retrieved 6 July 2022.
^ ab"Vectibix EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 13 August 2021. Retrieved 6 July 2022.
^"Illumina, Amgen to Develop CDx for Colorectal Cancer". News: Molecular Diagnostics. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. February 15, 2014. p. 32. Archived from the original on September 19, 2016. Retrieved December 2, 2014.
Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as...
tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab). This was the first genetic test to guide treatment of cancer. In July...
nerve palsy Anti-cancer treatments such as erlotinib, cetuximab, and panitumumab, which block the function of EGFR (the epidermal growth factor receptor)...
As of 2006, KRAS mutation was predictive of a very poor response to panitumumab (Vectibix) and cetuximab (Erbitux) therapy in colorectal cancer. As of...
often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate. In the short term, irinotecan...
2006: In April, Amgen acquired Abgenix, the developer of Vectibix (panitumumab), a treatment developed for certain patients with metastatic colorectal...
of which the three FDA approved ones are aflibercept, cetuximab and panitumumab. The primary difference in the approach to low stage rectal cancer is...
mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab. Brigatinib is an inhibitor of ALK and mutated EGFR. ALK was first identified...
AKT pathway. Panitumumab is a human mAb with high EGFR affinity that blocks ligand-binding to induce EGFR internalization. Panitumumab efficacy has been...
the ICG to antibodies such as daclizumab (Dac), trastuzumab (Tra), or panitumumab (Pan). ICG and laser therapy has been shown to kill human pancreatic...
already been available in the market, such as cetuximab (Erbitux) and panitumumab (Vectibix), both of which are directed against HER1. However, cancer...
colorectal cancer and squamous cell carcinoma of the head and neck. Panitumumab also targets the EGFR. It is approved for the use in the treatment of...
Global Information
(what is this?) (verify)